Cargando…

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

BACKGROUND: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challenges. We present a case study of a prospective–ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484825/
https://www.ncbi.nlm.nih.gov/pubmed/26137564
http://dx.doi.org/10.1016/j.ebiom.2015.02.005
_version_ 1782378716113928192
author Mendell, Jeanne
Freeman, Daniel J.
Feng, Wenqin
Hettmann, Thore
Schneider, Matthias
Blum, Sabine
Ruhe, Jens
Bange, Johannes
Nakamaru, Kenji
Chen, Shuquan
Tsuchihashi, Zenta
von Pawel, Joachim
Copigneaux, Catherine
Beckman, Robert A.
author_facet Mendell, Jeanne
Freeman, Daniel J.
Feng, Wenqin
Hettmann, Thore
Schneider, Matthias
Blum, Sabine
Ruhe, Jens
Bange, Johannes
Nakamaru, Kenji
Chen, Shuquan
Tsuchihashi, Zenta
von Pawel, Joachim
Copigneaux, Catherine
Beckman, Robert A.
author_sort Mendell, Jeanne
collection PubMed
description BACKGROUND: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challenges. We present a case study of a prospective–retrospective approach for a continuous biomarker identified after patient enrollment but defined prospectively before the unblinding of data. An analysis of the strengths and weaknesses of this approach and the challenges encountered in its practical application are also provided. METHODS: HERALD (NCT02134015) was a double-blind, phase 2 study in patients with non-small cell lung cancer (NSCLC) randomized to erlotinib with placebo or with high or low doses of patritumab, a monoclonal antibody targeted against human epidermal growth factor receptor 3 (HER3). While the primary objective was to assess safety and progression-free survival (PFS), a secondary objective was to determine a single predictive biomarker hypothesis to identify subjects most likely to benefit from the addition of patritumab. Although not identified as the primary biomarker in the study protocol, on the basis of preclinical results from 2 independent laboratories, expression levels of the HER3 ligand heregulin (HRG) were prospectively declared the predictive biomarker before data unblinding but after subject enrollment. An assay to measure HRG mRNA was developed and validated. Other biomarkers, such as epidermal growth factor receptor (EGFR) mutation status, were also evaluated in an exploratory fashion. The cutoff value for high vs. low HRG mRNA levels was set at the median delta threshold cycle. A maximum likelihood analysis was performed to evaluate the provisional cutoff. The relationship of HRG values to PFS hazard ratios (HRs) was assessed as a measure of internal validation. Additional NSCLC samples were analyzed to characterize HRG mRNA distribution. RESULTS: The subgroup of patients with high HRG mRNA levels (“HRG-high”) demonstrated clinical benefit from patritumab treatment with HRs of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively. However, only 102 of the 215 randomized patients (47.4%) had sufficient tumor samples for HRG mRNA measurement. Maximum likelihood analysis showed that the provisional cutoff was within the optimal range. In the placebo arm, the HRG-high subgroup demonstrated worse prognosis compared with HRG-low. A continuous relationship was observed between increased HRG mRNA levels and lower HR. Additional NSCLC samples (N = 300) demonstrated a similar unimodal distribution to that observed in this study, suggesting that the defined cutoff may be applicable to future NSCLC studies. CONCLUSIONS: The prospective–retrospective approach was successful in clinically validating a probable predictive biomarker. Post hoc in vitro studies and statistical analyses permitted further testing of the underlying assumptions. However, limitations of this analysis include the incomplete collection of adequate tumor tissue and a lack of stratification. In a phase 3 study, findings are being confirmed, and the HRG cutoff value is being further refined. CLINICALTRIALS.GOV NUMBER: NCT02134015.
format Online
Article
Text
id pubmed-4484825
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-44848252015-07-01 Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer Mendell, Jeanne Freeman, Daniel J. Feng, Wenqin Hettmann, Thore Schneider, Matthias Blum, Sabine Ruhe, Jens Bange, Johannes Nakamaru, Kenji Chen, Shuquan Tsuchihashi, Zenta von Pawel, Joachim Copigneaux, Catherine Beckman, Robert A. EBioMedicine Original Article BACKGROUND: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challenges. We present a case study of a prospective–retrospective approach for a continuous biomarker identified after patient enrollment but defined prospectively before the unblinding of data. An analysis of the strengths and weaknesses of this approach and the challenges encountered in its practical application are also provided. METHODS: HERALD (NCT02134015) was a double-blind, phase 2 study in patients with non-small cell lung cancer (NSCLC) randomized to erlotinib with placebo or with high or low doses of patritumab, a monoclonal antibody targeted against human epidermal growth factor receptor 3 (HER3). While the primary objective was to assess safety and progression-free survival (PFS), a secondary objective was to determine a single predictive biomarker hypothesis to identify subjects most likely to benefit from the addition of patritumab. Although not identified as the primary biomarker in the study protocol, on the basis of preclinical results from 2 independent laboratories, expression levels of the HER3 ligand heregulin (HRG) were prospectively declared the predictive biomarker before data unblinding but after subject enrollment. An assay to measure HRG mRNA was developed and validated. Other biomarkers, such as epidermal growth factor receptor (EGFR) mutation status, were also evaluated in an exploratory fashion. The cutoff value for high vs. low HRG mRNA levels was set at the median delta threshold cycle. A maximum likelihood analysis was performed to evaluate the provisional cutoff. The relationship of HRG values to PFS hazard ratios (HRs) was assessed as a measure of internal validation. Additional NSCLC samples were analyzed to characterize HRG mRNA distribution. RESULTS: The subgroup of patients with high HRG mRNA levels (“HRG-high”) demonstrated clinical benefit from patritumab treatment with HRs of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively. However, only 102 of the 215 randomized patients (47.4%) had sufficient tumor samples for HRG mRNA measurement. Maximum likelihood analysis showed that the provisional cutoff was within the optimal range. In the placebo arm, the HRG-high subgroup demonstrated worse prognosis compared with HRG-low. A continuous relationship was observed between increased HRG mRNA levels and lower HR. Additional NSCLC samples (N = 300) demonstrated a similar unimodal distribution to that observed in this study, suggesting that the defined cutoff may be applicable to future NSCLC studies. CONCLUSIONS: The prospective–retrospective approach was successful in clinically validating a probable predictive biomarker. Post hoc in vitro studies and statistical analyses permitted further testing of the underlying assumptions. However, limitations of this analysis include the incomplete collection of adequate tumor tissue and a lack of stratification. In a phase 3 study, findings are being confirmed, and the HRG cutoff value is being further refined. CLINICALTRIALS.GOV NUMBER: NCT02134015. Elsevier 2015-02-12 /pmc/articles/PMC4484825/ /pubmed/26137564 http://dx.doi.org/10.1016/j.ebiom.2015.02.005 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Mendell, Jeanne
Freeman, Daniel J.
Feng, Wenqin
Hettmann, Thore
Schneider, Matthias
Blum, Sabine
Ruhe, Jens
Bange, Johannes
Nakamaru, Kenji
Chen, Shuquan
Tsuchihashi, Zenta
von Pawel, Joachim
Copigneaux, Catherine
Beckman, Robert A.
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
title Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
title_full Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
title_fullStr Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
title_full_unstemmed Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
title_short Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
title_sort clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (her3) monoclonal antibody, in patients with advanced non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484825/
https://www.ncbi.nlm.nih.gov/pubmed/26137564
http://dx.doi.org/10.1016/j.ebiom.2015.02.005
work_keys_str_mv AT mendelljeanne clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT freemandanielj clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT fengwenqin clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT hettmannthore clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT schneidermatthias clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT blumsabine clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT ruhejens clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT bangejohannes clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT nakamarukenji clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT chenshuquan clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT tsuchihashizenta clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT vonpaweljoachim clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT copigneauxcatherine clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer
AT beckmanroberta clinicaltranslationandvalidationofapredictivebiomarkerforpatritumabanantihumanepidermalgrowthfactorreceptor3her3monoclonalantibodyinpatientswithadvancednonsmallcelllungcancer